Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 2/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20594008 | 1.00 | CPN1 (0.41) | CPN1CPB2KDM4EMAPTKMT2A | |
| SCHEMBL20594016 | 1.00 | CPN1 (0.41) | CPN1CPB2KDM4EMAPTKMT2A | |
| SCHEMBL7390438 | 0.91 | SLC6A1 (0.33) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL4312543 | 0.91 | SLC6A1 (0.33) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL7383261 | 0.91 | SLC6A1 (0.33) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL2001522 | 0.84 | NOS1 (0.34) | NOS2 | |
| SCHEMBL3878210 | 0.83 | CPN1 (0.42) | CPN1CPB2KDM4EMAPTKMT2A | |
| Hydrochloric Acid SCHEMBL29940301 | 0.82 | NOS1 (0.33) | NOS2 | |
| SCHEMBL27570839 | 0.82 | DPP4 (0.41) | EPHX1BTK | |
| SCHEMBL27371104 | 0.82 | CPN1 (0.41) | CPN1CPB2KDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775346-A | E3 ubiquitin ligase ligand compound and application thereof | 天津医科大学 | 2025-04-08 | — | — | CN | disclosed |
| US-20250002455-A1 | NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY | UNIV LJUBLJANI (SI) | 2025-01-02 | — | — | US | disclosed |
| US-20240199630-A1 | IMIDAZO[1,2-B]PYRIDAZINE BASED TRICYCLIC COMPOUNDS AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2024-06-20 | — | — | US | disclosed |
| EP-4313990-A1 | IMIDAZO[1,2-B]PYRIDAZINE BASED TRICYCLIC COMPOUNDS AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2024-02-07 | — | — | EP | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116997548-A | HTT modulators for the treatment of huntington's disease | CHDI基金会股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-4263503-A1 | NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY | Univerza V Ljubljani (SI) | 2023-10-25 | — | — | EP | disclosed |
| CN-112538083-B | Aromatic ring penta aromatic heterocyclic micromolecule organic compound targeting BCL6, derivative thereof and application thereof | 华东师范大学 | 2023-04-28 | — | — | CN | disclosed |
| EP-4149937-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI Foundation, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-3887370-B1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| WO-2010033198-A2 | ANALOGS OF INDOLE-3-CARBINOL AND THEIR USE AS AGENTS AGAINST INFECTION | SRI INTERNATIONAL (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069355-A1 | Analogs of Indole-3-Carbinol and Their Use as Agents Against Infection | UNITED STATES GOVERNMENT; DEFENSE THREAT REDUCTION AGENCY | 2010-03-18 | — | — | US | disclosed |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-7429597-B2 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-09-30 | — | — | US | disclosed |
| WO-2008016811-A2 | AMINOPIPERIDINES AND REALTED COMPOUNDS | NEUROGEN CORPORATION (US) | 2008-02-07 | — | — | WO | disclosed |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| EP-0729472-A4 | PIPERIDINYLCAMPHORSULFONYL OXYTOCIN ANTAGONISTS | MERCK & CO INC (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0729472-A1 | PIPERIDINYLCAMPHORSULFONYL OXYTOCIN ANTAGONISTS | MERCK & CO. INC. (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995014025-A1 | PIPERIDINYLCAMPHORSULFONYL OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1995-05-26 | — | — | WO | disclosed |
| EP-0486280-A2 | Piperidinylcamphorsulfonyl oxytocin antagonists | MERCK & CO. INC. (US) | 1992-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002455-A1 | NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY | TOP1, TOP2A, TOP2B | CPN1 373/4885CPB2 1008/4885KDM4E 963/4885 |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | F11, F12, F2 | CPN1 912/4885CPB2 186/4885KDM4E 4499/4885 |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | CPN1 3530/4885CPB2 4357/4885KDM4E 3315/4885 |
| US-20100069355-A1 | Analogs of Indole-3-Carbinol and Their Use as Agents Against Infection | IDO1, IDO2, TDO2 | CPN1 1375/4885CPB2 2307/4885KDM4E 3668/4885 |
| US-20240199630-A1 | IMIDAZO[1,2-B]PYRIDAZINE BASED TRICYCLIC COMPOUNDS AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF | HASPIN, CIAPIN1, MKI67 | CPN1 583/4885CPB2 716/4885KDM4E 4342/4885 |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | CPN1 1366/4885CPB2 255/4885KDM4E 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.